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Abstract 
 
Twelve novel β-lactams were synthesised and their antiproliferative effects and binding 
affinity for the predominant isoforms of the estrogen receptor (ER), ERα and ERβ, were 
determined. β-Lactams 23 and 26 had the strongest binding affinities for ERα (IC50 
values: 40 and 8 nM respectively) and ERβ (IC50 values: 19 and 15 nM). β-Lactam 26 
was the most potent in antiproliferative assays using MCF-7 breast cancer cells, and 
further biochemical analysis showed that it caused accumulation of cells in G2/M phase 
(mitotic blockade) and depolymerisation of tubulin in MCF-7 cells. Compound 26 also 
induced apoptosis and downregulation of the pro-survival proteins Bcl-2 and Mcl-1. 
Computational modeling predicted binding preferences for the dual ER/tubulin ligand 26. 
This series is an important addition to the known pool of ER antagonists and β-lactam 26 
is the first reported compound that has dual-targeting properties for both the ER and 
tubulin. 
 
Key words 
Antiproliferative, azetidinone, designed multiple ligand, estrogen receptor, β-lactam, 
polypharmacy, SERM, tubulin 
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Introduction 
Estrogen receptors (ERs) belong to the superfamily of nuclear receptors, which includes 
steroid receptors, thyroid receptors and vitamin D receptors.1 The ER is a ligand-
activated transcriptional regulator that mediates the effects of the endogenous hormone 
17β-estradiol (1, Figure 1). ERs possess two activation domains (AF1 and AF2) that 
promote interactions with co-regulator proteins and facilitate transcriptional activation of 
target gene expression.2 Approximately 75% of breast tumours express ER3 and treatment 
of breast cancer with ER antagonists contributes to a dramatic reduction in breast cancer 
mortality.4-5 Tamoxifen (2, Figure 1) is a synthetic, non-steroidal anti-estrogenic drug 
used clinically for the treatment of breast cancer.1 It is metabolically activated in vivo into 
4-hydroxytamoxifen and N-desmethyltamoxifen followed by secondary metabolism to 4-
hydroxy-N-desmethyltamoxifen (endoxifen).6 Compound 2 has high binding affinity for 
the ER and it is termed a selective estrogen receptor modulator (SERM) as it exhibits 
tissue-dependent effects, imitating the action of estrogens in certain tissues while 
opposing their action in others.2 Compound 2 was the first clinically successful SERM 
that acted as an antagonist at the ER in breast tissue and prevented estrogen-stimulated 
breast tumour growth.7 Recent clinical guidelines recommend the prophylactic use of 2 
for particular groups of women with a family history of cancer.8 The main concerns 
regarding usage of 2, namely increased incidences of blood clots and endometrial cancer, 
are linked to its estrogen-like properties in postmenopausal women.7 Raloxifene (3, 
Figure 1) was the first of the 2,3-disubstituted benzothiophene group of SERMs to be 
introduced into clinical use for the treatment of osteoporosis in postmenopausal women.9 
It has the additional benefits of preventing coronary heart disease and breast cancer.4 At a 
 4 
 
molecular level, the basic side-chain of 3 interferes with exposure of the AF1 and AF2 
sites and prevents interaction with nuclear receptor co-activators.4 Many alternative non-
isomerisable scaffolds for ER modulators have been reported, e.g. tetrahydronaphthalene 
(lasofoxifene),10 pyrazole,11 tetrahydroisoquinoline,12 benzopyran (EM-652)13 and 
dihydrobenzoxathiin.14 Carbocyclic and heterocyclic core scaffolds have been reported as 
ER agonist ligands e.g. the isoflavone genistein (4),15 the propylpyrazole triol (PPT) 5,16 
the benzoxazole ERB041 (6)15 and the 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide type ligand 
7 (Figure 1).17 
 
We have previously reported the antiproliferative activity of SERM-type compounds 
containing the β-lactam (azetidinone) scaffold with a basic side-chain which 
demonstrated antiestrogenic effects in MCF-7 cells (e.g. β-lactam 8, Figure 1).18 As part 
of our ongoing interest in the development of ER ligands having novel scaffold structures 
we therefore decided to investigate a related series of β-lactams to identify potential lead 
compounds for further development as ERα or ERβ ligands. We were also interested in 
finding a common scaffold for the development of designed multiple ligands targeting 
both the ER and tubulin. Tubulin is an  heterodimeric protein and is the main 
constituent of microtubules, which are essential to the mitotic division of cells. Many 
tubulin binding compounds, such as paclitaxel and vinblastine, are in clinical use for 
various types of cancer.19 There are a number of potential advantages for designed 
multiple ligands, for example, improved efficacy, less incidence of side effects and a 
lower risk of drug-drug interactions.20-22 A large number of dual-ligands are progressing 
in clinical trials, including the novel drug conjugate trastuzumab emtansine (T-DM1) 
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which is in phase III clinical trials for Her-2 positive breast cancer. It combines the 
distinct mechanism of action of both DM1 (a microtubule inhibitor) and trastuzumab.23 A 
designed multiple ligand targeting both the ER and tubulin is potentially of clinical use in 
cases where a microtubule inhibitor is combined with a SERM, e.g. the combination of 
paclitaxel and tamoxifen.24 Our novel compounds were assessed for their binding 
affinities for ERα and ERβ and their antiproliferative activities in MCF-7 cells. Selected 
compounds were further assessed for their effects on the cell cycle and tubulin 
polymerisation. Finally, a computational study was undertaken to investigate the binding 
orientation of the most potent and selective compounds.  
 
Chemistry 
The β-lactam ring scaffold is the template for a variety of drugs and preclinical 
compounds including antibiotics, tubulin-targeting agents,25-29 SERMs,18 cholesterol-
absorption inhibitors30 and anti-asthmatics.31 The two most common routes for synthesis 
of the β-lactam core are the Staudinger32-33 and Reformatsky34 reactions and both of these 
reactions were utilised in the synthesis of the required ER targeting β-lactams. The β-
lactams reported herein incorporate the characteristic pharmacophore for ER binding, 
namely a hydrophobic core with two phenolic groups approximately 11 Å apart (Schemes 
2 and 3).35 An unsubstituted β-lactam ring is not inherently hydrophobic, but the presence 
of aromatic rings at C-1 and C-4 increases the hydrophobicity of this series substantially. 
The newly reported compounds have similar spatial arrangements to many SERMs, but 
the majority lack the basic, nitrogen-containing ether substituent characteristic of many 
SERMs such as 3. The preparation of precursors to the β-lactam ring-forming reactions 
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involved synthesis of appropriately protected imines. Tert-butyldimethylsilane (TBDMS) 
and benzyl (Bn) groups were used to protect phenol groups and were chosen due to their 
ease of introduction, stability under the conditions of both the Staudinger and 
Reformatsky reactions, and ease of removal without decomposition of the β-lactam ring. 
Imines 10-14 were obtained by condensation of the appropriate amines and aldehydes 
under reflux conditions in ethanol (Scheme 1). 
 
β-Lactams 15-18 were obtained by a Reformatsky-type reaction of a series of 
appropriately substituted imines with ethyl bromoacetate under microwave conditions to 
afford the 3-unsubstituted products (Scheme 2). β-Lactams 19-24 were synthesised from 
imine 10, and β-lactam 25 from imine 11, by the Staudinger route using triethylamine as 
tertiary base (Scheme 2). The β-lactams were deprotected in situ before final 
characterisations were carried out (reaction monitored by IR and TLC). Both TBDMS 
and Bn protecting groups were successfully removed without decomposition of the β-
lactam ring (Scheme 2). For compounds 19-22, 24 and 25 the 1H NMR spectrum showed 
formation of the product exclusively as the trans isomer as evidenced by the coupling 
constant between H-3 and H-4 of the β-lactam ring [e.g. for compound 25: δ 4.20 (d, 1H, 
J = 2.5 Hz, H3), 4.78 (d, 1H, J = 2.5 Hz, H4)]. 
 
A structurally related group of compounds containing the common β-lactam core 
structure substituted with aryl rings at the N-1 and C-4 positions, together with the 
arylhydroxymethyl substituent at C-3, were also prepared to provide further insight on 
the structural requirements of the β-lactam scaffold for ER binding activity. The 
 7 
 
introduction of the required substituent at the C-3 position was achieved with an aldol 
type reaction of a suitable phenolic aldehyde to produce the-(hydroxyaryl)methyl group 
at the C-3 position of the -lactam.36 Reaction of 16, 17 and 18 with 4-
hydroxybenzaldehyde afforded the products 26, 27 and 29 respectively (Scheme 3). 
Debenzylation of 27 yielded the required triphenolic product 28. Alkylation of 26 with 1-
(2-chloroethyl)pyrrolidine hydrochloride resulted the isolation of the ether product 30, 
which contains a basic side-chain similar to known SERMs (Scheme 3). This substituent 
was previously identified as the optimal basic side-chain for SERM activity in β-
lactams.18 The products were obtained as diastereomeric mixtures evident from the 1H 
NMR spectra, e.g. compound 26 was obtained in a 3:1 ratio, compound 29 in a 3:2 ratio 
and compounds 28 and 30 in a 1:1 ratio. 
 
Biochemical Evaluation 
The binding affinities of the novel β-lactams for ER and ER was assessed using a 
competitive binding assay with a fluorescent estrogen ligand. Compound 1 was included 
as a positive control and had an IC50 value of 5.7 nM in ERα and 5.6 nM in ERβ 
consistent with reported literature values.15, 37-38 SERM 2 was also evaluated and had an 
IC50 value of 61 nM in ERα and 190 nM in ERβ. Many SERMs contain two phenolic 
groups to mimic the hydroxyl groups of 1. Initially a series of six compounds (15 and 19-
23, Scheme 2) with phenolic substitutions at N-1 and C-4 but with a variety of 
substituents at C-3 was evaluated. A clear pattern of activity for these compounds can be 
observed, with smaller substituents at C-3 leading to decreased affinity in the ER binding 
assay compared to larger substituents (Table 1). The potency increases in the order of 
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unsubstituted 15<phenyl 19<phenoxy 21<2-naphthyl 22<diphenyl 23. The least potent 
compound of this mini-series, 15, is unsubstituted at position 3 and has an IC50 value in 
ERα of 13 μM. 3, 3-Diphenyl compound 23 binds strongly with IC50 values of 0.04 μM 
(ERα) and 0.019 μM (ERβ). The calculated distance between the oxygen atoms of the 
phenolic groups at positions 1 and 4 of the β-lactam ring of 23 is 9.4 Å,39 which 
compares with a value of 10.8 Å for the distance between the hydroxyl groups in 1. It is 
possible that the bulkier C-3 substituents interfere with exposure of the AF1 and AF2 
sites in a similar manner to the basic side-chain of 3. However, with the exception of 
previously reported compound 16, compound 23 was the only β-lactam in Scheme 2 to 
display antiproliferative activity in MCF-7 cells at concentrations < 50 µM (IC50=45 
μM).  
 
The relative lack of antiproliferative activity for the majority of compounds in the series 
prompted us to examine their binding mode to determine if the compounds were ER 
agonists. The structures of β-lactams 15-23 lack the conventional basic side chain present 
in most ER antagonists such as 2 and 3, and therefore could be expected to resemble the 
ER agonist core structures of 4 (Figure 1, ER agonist/partial ER agonist),15 THC 
(5R,11R-diethyl,5,6,11,12-tetrahydrochrysene-2,8-diol) (ER agonist),40 propyl pyrazole 
triol (PPT) (ERagonist)16 and the benzothiophene raloxifene core (ER agonist).41 As a 
representative example of the compounds with no antiproliferative activity, β-lactam 20 
was assessed in a TR-FRET assay to determine if the compound was acting as an agonist 
or antagonists for ER. The IC50 value for 20 in the TR-FRET assay (1.4 μM) was in 
agreement with the value of 1.1 μM obtained in the fluorescence polarisation assay. 
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Compound 20 was inactive in the agonist mode but active in the antagonist mode, 
confirming that β-lactam 20 is acting as an ERα antagonist. This is not unprecedented, as 
both 1,1,2-tris(4-hydroxyphenyl)alkenes and 7-oxabicyclo[2.2.1]hept-5-enes (OBHS) are 
known as ER antagonists, despite lacking the basic side chain substituent typically 
required for these effects.42-43 Hence, the lack of antiproliferative activity is due to other 
factors. The ER assay uses isolated estrogen receptor and is not a cell-based assay, and β-
lactam degradation is unlikely to occur in these conditions. However, the presence of 
cellular enzymes in the cellular viability assay in MCF-7 cells could cause metabolic 
deactivation by opening the β-lactam ring, e.g. by hydrolysis, leading to a decrease in the 
in vitro antiproliferative effect. 
 
We focused our further efforts on the development of a dual ligand for ER and tubulin. It 
is known that a trimethoxyaryl ring, found in the natural products colchicine and 
combretastatin A-4 as well as in tubulin-targeting β-lactams, contributes to strong 
interactions with the colchicine-binding site of tubulin.26, 44 We incorporated this group 
into an ER pharmacophore containing two phenolic groups in the molecule. Comparison 
of the binding affinities of compounds 24 and 25 indicated that positioning of phenolic 
rings at N-1 and C-4 positions gave more potent antiproliferative activity than when they 
were located at N-1 and C-3. β-Lactam 24 had 10-fold greater binding affinity than 25 in 
ERα binding (IC50=1.47 μM and 17.5 μM respectively). The same pattern was 
determined for ERβ [IC50=23 μM (24) and 144 μM (25)]. However, neither β-lactam 24 
nor 25 displayed antiproliferative activity in MCF-7 cells at concentrations up to 50 μM. 
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Compound 16, previously reported as a tubulin-targeting β-lactam and included here for 
comparative purposes, showed no ER binding affinity.  
 
In an attempt to improve the antiproliferative activity, whilst maintaining the ER binding 
affinity, compounds with a α-(hydroxyaryl)methyl substituent at C-3 were prepared (26, 
28 and 29, Scheme 3). Compound 26 was identified as a potent compound in the series 
with IC50 values of 0.008 μM (ERα) and 0.015 μM (ERβ). Compounds 28 and 29 did not 
bind strongly to either ERα or ERβ in comparison to compound 26 (Table 1). 
Compounds 28 and 29 were also not potent antiproliferative compounds in MCF-7 cells 
whereas the antiproliferative activity of β-lactam 26 was the best of all the ER binding 
compounds, with an IC50 of 0.21 µM. The subsequent introduction of the basic 
pyrrolidine SERM-type ether substituent in 30 resulted in elimination of the ER binding 
activity from the core β-lactam structure of 26. This compound shows no affinity for 
either ERα or ERβ in the competitive binding assay so it can be assumed that this is not 
the mechanism of action of 30. Compound 30 also has a reduced antiproliferative effect 
compared to compound 26 (IC50=3.80 M). Compound 30 is structurally similar to our 
previously reported ER binding β-lactam 8 [Figure 1, IC50=4.63 μM (MCF-7)18], and the 
loss of activity indicates that the trimethoxy-substitution at N-1 is detrimental to ER 
binding affinity for this particular compound. Although compound 30 incorporates a 
basic-side chain, it does not contain two phenolic groups and this may explain its lack of 
ER binding affinity.  
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Further biochemical characterization was carried out on β-lactams 16, 26 and 30. 
Compound 26 was amongst the compounds with the highest affinity for ERα and ERβ in 
the competitive binding assays and the most potent antiproliferative activity in MCF-7 
cells. Cytotoxic effects were evaluated using the lactate dehydrogenase assay. 1.5%, 10% 
and 7% cell death was observed in MCF-7 cells for compounds 16, 26 and 30 
respectively at 10 M (compound 2 as a control demonstrated 13% cell death at 10 M; 
β-lactam 8 has been reported to cause 14.8% cell death in MCF-7 cells at 10 μM18). Flow 
cytometric analysis was performed to observe the effects of 16, 26 and 30 on the cell 
cycle distribution of MCF-7 cells after 24 hours and to quantify the extent of G2/M arrest 
and sub-G1 arrest induced by these compounds (Figure 2.A). Compound 16, structurally 
similar to known tubulin inhibitors25, caused accumulation of cells in G2/M arrest at 
concentrations of 100 nM and above. There is also a significant increase in sub-G1 cells 
at concentrations of 1 µM and 10 µM indicating induction of apoptosis even after 24 
hours. There were increased numbers of cells in sub-G1 at concentrations of 10 nM and 
above of compound 30, indicative of apoptosis. There was also an increase in the 
percentage of cells in G2/M phase for compound 30 (10 µM). Compound 26 (1 µM and 
10 µM) also caused accumulation of cells in G2/M phase indicating mitotic blockage at 
24 hr. Additional flow cytometry experiments were performed at 48 and 72 hr for 
compound 26 in order to investigate if the percentage of cells in sub-G1 increased at 
extended time-points (Figure 2.B). No significant differences compared to vehicle control 
were observed at 24 hr. There was an increase in % of sub-G1 cells for compound 26 at 
48 hr (9.3% compared to 1.9% for control) and a statistically significant difference was 
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observed at 72 hr (17% compared to 3.7% for control). This indicates that compound 26 
causes prolonged G2/M arrest followed by apoptosis. 
 
The potential tubulin-targeting properties of β-lactam 26 were investigated using a 
sedimentation assay and Western blotting (Figure 3). Paclitaxel and nocodazole served as 
controls; paclitaxel promotes the polymerization of tubulin and nocodazole is a tubulin 
depolymerizer.  Polymerized and depolymerized microtubules have different solubilities 
and localize in either the pellet or supernatant of lysed, centrifuged cells, respectively. 
Tubulin from nocodazole-treated cells was depolymerized and detected almost wholly in 
the supernatant, whereas tubulin from paclitaxel-treated cells was polymerized and 
detected solely in the pellet (Figure 3). Tubulin from β-lactam 26-treated cells (1 μM) 
was found exclusively in the supernatant, indicating complete depolymerization of 
tubulin (Figure 3). This confirmed that compound 26 is acting as a tubulin depolymerizer 
in addition to its ER targeting properties.  
 
The effects of other tubulin-targeting agents mediating signal transduction pathways of 
apoptosis have been previously described.45-47 Anti-apoptotic proteins of the Bcl-2 family 
contribute to an increased apoptotic threshold in cancer cells and allow cells to survive in 
stressful environments.48 We examined the effects of compound 26 on two anti-apoptotic 
members of the Bcl-2 family, Bcl-2 and Mcl-1, in MCF-7 cells. Western blotting of the 
pro-survival proteins Bcl-2 and Mcl-1 showed decreases in both at 72 hrs (Figure 4), 
indicating downregulation of expression of these proteins upon treatment with compound 
26. Decreases in the level of Bcl-2 were also seen at 48 hrs (data not shown). In 
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combination with cell cycle analysis (above), this result indicates that compound 26 
induces apoptosis in MCF-7 cells. 
 
An increasing number of designed multiple ligands for cancer therapy are known.22 
Combretastatin A-4/steroid hybrids that inhibit the polymerisation of tubulin have been 
reported but the ER binding affinity of these compounds is unknown.49 To the best of our 
knowledge, β-lactam 26 is the first reported compound that is a designed multiple ligand 
targeting both the estrogen receptor and tubulin. Lead optimization will be required to 
determine the optimal ratio of activity that enables both targets to be modulated to an 
appropriate degree in vivo. This is an exciting discovery that provides a lead compound 
targeting two clinically relevant targets in breast cancer therapy.  
 
Computational Modelling 
 
The majority of structural studies on the ER focus on the ligand-binding domain (LBD). 
The LBD crystal structures for ERα with the natural hormone agonist 1 and ER 
antagonists 2 and 3 have been reported, amongst others.40, 50 High resolution x-ray crystal 
structures of the ER LBD bound to a range of steroidal and non-steroidal ligands allow 
some rationalisation of the SARs observed for various ligand classes at the steroid 
receptor.2  
 
We examined computational docking in ERα and tubulin for the dual-targeting β-lactam 
26. Figure 5 illustrates the binding pose of compound 26 docked in the binding site of 
ERα and importantly H-bonding with Glu353 and a π-stacking interaction with Phe404 
are present as are commonly observed with many ER binding ligands.2 These interactions 
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occur between the receptor and the arylhydroxymethyl substituent at C-3 of the β-lactam. 
Current ‘state-of-the-art’ docking and scoring algorithms have difficulty in accurately 
prioritising a series of analogs and by inference one can assume similar problems may 
occur in effectively ranking stereoisomers and their enantiomers of a compound. Figure 
S1 (supporting information) illustrates the orientation of the top five docking poses and 
indicates that all adopt a highly similar geometry in the binding site of ERα. It is also 
important to note that only two of all possible stereoisomers of compound 26 are present 
in the top 5 docked and scored solutions generated by HYBRID (Table S1, Supporting 
Information).  
 
Our biochemical data indicates that compound 26 causes depolymerisation of tubulin, 
most probably through binding in the colchicine site. Figure 6 illustrates the binding 
orientation of 26 overlaid with the binding orientation of colchicine, whereby similar 
interactions with the important trimethoxyphenyl moiety and solvent bridging Cys239 are 
made for compound 26 as for colchicine.44, 51 Other interactions such as σ-π bonding to 
Leu253 occur to stabilise compound 26 in the tubulin binding site. Interestingly, the top 
docked solution as represented in Figure S1 which depicts compound 26 in the colchicine 
binding site is the following: (3R,4R)-3-[(R)-hydroxy-(4-hydroxyphenyl)methyl]-4-(4-
methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one. This is the same form that is 
represented in 3 of the 5 top docked solutions bound to ERα (Table S2, Supporting 
Information).  
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Conclusion 
A series of ER ligands were synthesised and evaluated for ER binding and 
antiproliferative activity. The most potent β-lactam in the antiproliferative assay, 26, was 
demonstrated to be a designed multiple ligand targeting both the ER and tubulin, causing 
complete depolymerisation of tubulin in MCF-7 cells. It was also shown to induce 
apoptosis and downregulated the levels of anti-apoptotic proteins Bcl-2 and Mcl-1 in 
MCF-7 cells. These compounds represent an interesting and novel class of ER antagonist, 
and may have future potential applications as medicinal agents for anti-cancer use or 
mediation of inflammatory response. β-Lactam 26 has been identified as a lead 
compound for further investigations in the design of new compounds with enhanced 
affinity for both the ER and tubulin. 
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Experimental Section  
General Chemical Synthesis and Analysis 
All reagents were commercially available and were used without further purification 
unless otherwise indicated. DCM was dried by distillation from calcium hydride prior to 
use. IR spectra were recorded as thin films on NaCl plates or as KBr discs on a Perkin-
Elmer Paragon 100 FT-IR spectrometer. 1H and 13C NMR spectra were obtained on a 
Bruker Avance DPX 400 instrument at 20 oC, 400.13 MHz for 1H spectra, 100.61 MHz 
for 13C spectra, in either CDCl3 or CD3OD (internal standard tetramethylsilane). High 
resolution accurate mass determinations for all final target compounds were obtained on a 
Micromass Time of Flight mass spectrometer equipped with electrospray ionization 
interface operated in the positive ion mode at the High Resolution Mass Spectrometry 
Laboratory by Dr. Martin Feeney in the School of Chemistry, Trinity College Dublin. 
TLC was performed using Merck Silica gel 60 TLC aluminium sheets with fluorescent 
indicator visualizing with UV light at 254 nm. Flash chromatography was carried out 
using standard silica gel 60 (230-400 mesh) obtained from Merck. All products isolated 
were homogenous on TLC. The purity of the tested compounds was determined by HPLC 
and unless otherwise stated, the purity level was >95%. HPLC was performed using a 
Waters 2487 Dual Wavelength Absorbance detector, a Waters 1525 binary HPLC pump 
and a Waters 717plus Autosampler. The column used was a Varian Pursuit XRs C18 
reverse phase 150 x 4.6 mm chromatography column. Samples were detected using a 
wavelength of 254 nm. All samples were analyzed using acetonitrile (70%): water (30%) 
over 10 min and a flow rate of 1 mL/min. Imine 12 and β-lactam 16 (43% yield) were 
synthesised as previously described.25 
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4-(tert-Butyldimethylsilanyloxy)phenylamine (9). To a solution of 4-aminophenol (20 
mmol) and dimethyl-tert-butylchlorosilane (24 mmol) in anhydrous CH2Cl2 (60 mL) was 
added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (32 mmol). The resulting mixture was 
stirred at room temperature under a nitrogen atmosphere until complete, as indicated by 
TLC. The solution was then diluted with CH2Cl2 (80 mL) and washed successively with 
water (60 mL), 0.1M HCl (60 mL) and saturated aqueous NaHCO3 (60 mL). The organic 
layer was dried over anhydrous Na2SO4 to afford the product as a brown oil (73% 
yield).52 1H NMR (CDCl3) δ 0.12 (m, 6H, SiCH3), 0.94 (m, 9H, CH3), 3.92 (m, 2H, NH2), 
6.81 (m, 4H, ArH). 13C NMR (CDCl3) δ -4.91 (SiCH3), -4.04 (SiCH3), 17.73 (SiC), 
116.79, 120.18, 120.29, 137.86, 148.64. HRMS (ESI): m/z calcd for C12H21NOSi + H
+ (M 
+ H)+: 224.1465; found: 224.1180. 
 
General method I: imine preparation. The appropriate amine (10 mmol) was heated at 
reflux with the appropriate aldehyde (10 mmol) in ethanol (50 mL) for 3 h. The solvent 
was removed in vacuo and the resulting solid product was purified by recrystallisation 
from ethanol. 
 
(4-Benzyloxybenzylidene)-[4-(tertbutyldimethylsilanyloxy)phenyl]amine (10) was 
prepared from 9 and 4-benzyloxybenzaldehyde as white crystals according to general 
method I (82% yield), mp 146 °C. IR (KBr): ν̃ = 1626 cm-1 (s; ν(C=N)). 1H NMR 
(CDCl3) δ 0.24 (m, 6H, -SiCH3), 0.99 (m, 9H, CH3), 5.18 (s, 2H, OCH2), 6.93 (m, 4H, 
ArH), 7.12 (m, 2H, ArH), 7.42 (m, 5H, ArH), 7.86 (m, 1H, ArH), 8.43 (s, 1H, CH=N). 
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13C NMR (CDCl3) δ -4.93 (SiCH3), -4.85 (SiCH3), 17.79 (SiC), 25.18 (CH3), 25.25 (SiC), 
69.82 (OCH2), 114.69, 115.58, 119.94, 120.52, 120.62, 120.81, 121.97, 122.84, 125.14, 
127.06, 127.13, 127.91, 128.03, 128.30, 128.34, 131.57, 135.47 (ArC), 190.39 (CH=N). 
HRMS (ESI): m/z calcd for C26H31NO2Si + H
+ (M + H)+: 418.2197; found: 418.2216. 
 
4-(tert-Butyldimethylsilyloxy)-N-(3,4,5-trimethoxybenzylidene)aniline (11) was 
obtained from 9 and 3,4,5-trimethoxybenzenamine according to general method I. The 
product 11 was obtained as a brown oil in quantitative yield which was used without 
further purification. IR (NaCl): ν̃ = 1623 cm-1 (s; ν(C=N)). 1H NMR (CDCl3) δ 0.04 (s, 
6H, 2xCH3), 0.84 (s, 3H, CH3), 0.96 (s, 6H, 2xCH3), 3.73( s, 3H, OCH3), 3.86 (6H, s, 
2xOCH3), 7.797.25 (6H, m, ArH), 8.53(s, 1H, CH=N). 
13C NMR (CDCl3) δ -4.52 (-
SiCH3), -3.21 (-SiCH3), 17.94, 25.54 (CH3), 55.86 (OCH3), 60.13 (OCH3), 105.55, 
115.70, 120.37, 122.32, 132.00, 144.94, 153.10, 153.56 (ArC) 158.49 (CH=N). HRMS 
(ESI): m/z calcd for C22H31NO4Si + H
+ (M + H)+: 402.2095; found: 402.2083. 
 
N,1-bis(4-(benzyloxy)phenyl)methanimine (13) was prepared from 4-
benzyloxybenzaldehyde and 4-(benzyloxy)aniline according to general method I. The 
product 13 was obtained as a pale green solid (74% yield), mp 210-212 °C. IR (KBr): ν̃ = 
1615 cm-1 (s; ν(C=N)). 1H NMR (CDCl3) δ 5.11 (s, 2H, OCH2Ph), 5.16 (s, 2H, OCH2Ph), 
7.02 (d, J = 8.5 Hz, 2H, ArH), 7.08 (d, J = 8.5 Hz, 2H, ArH), 7.32 (d, J = 8.5 Hz, 2H, 
ArH), 7.36-7.49 (m, 10H, ArH), 7.87 (d, J = 8.0 Hz, ArH), 8.42 (s, 1H, HC=N). 13C 
NMR (CDCl3) δ 69.6 (OCH2), 69.8 (OCH2), 114.6, 114.9, 121.6, 127.1, 127.6, 127.7, 
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128.2, 128.2, 129.9, 123.0, 136.5, 153.6, 156.8 (ArC) 157.5 (HC=N). HRMS (ESI): m/z 
calcd for C27H23NO2 + H
+ (M + H)+: 394.1802; found: 394.1812. 
 
N-(4-Methoxybenzylidene)-4-anisidine (14) was prepared from 4-methoxyaniline and 
4-methoxybenzaldehyde according to general method I. The product 14 was obtained 
from ethanol as mint green coloured crystals (79% yield), mp 148 °C - 150 °C.53 IR 
(KBr): ν̃ = 1623 cm-1 (s; ν(C=N)). 1H NMR (CDCl3): δ 3.85 (s, 3H, OCH3), 3.89 (s, 3H, 
OCH3), 6.93-7.00 (m, 4H, ArH), 7.22 (d, 2H, J = 9.0 Hz, ArH, 7.84-7.86 (m, 2H, ArH), 
8.42 (s, 1H, -CH=N). 13C NMR (CDCl3): δ 55.4 (OCH3), 55.5 (OCH3), 114.2, 114.4, 
122.0, 129.6, 130.2, 145.3, 157.8, 157.9 (ArC), 162.1 (CH=N). HRMS (ESI): m/z calcd 
for C15H15NO2 + H
+ (M + H)+: 242.1176; found: 242.1192. 
 
General method II: β-lactam preparation (Staudinger-type reaction). The 
appropriate imine (5 mmol) and triethylamine (15 mmol) were added to anhydrous 
CH2Cl2 (50 mL) in an inert atmosphere and the mixture was refluxed at 60 °C. The 
appropriately substituted acid chloride (7.5 mmol) was injected dropwise and the mixture 
was refluxed for 3 hours. Upon cooling to room temperature, the mixture was twice 
washed with distilled water (50 mL) and once with saturated aqueous NaHCO3 solution 
(50 mL). The organic layer was dried by filtration through anhydrous Na2SO4. The 
organic layer containing the product was reduced in vacuo. The crude product was 
isolated by flash column chromatography over silica gel (hexane: ethyl acetate gradient).  
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General method III: β-lactam preparation (Reformatsky-type reaction). Zinc powder 
(15 mmol) was activated using trimethylchlorosilane (5 mmol) in anhydrous benzene (5 
mL) by heating for 15 min at 40 °C and subsequently for 2 min at 100 °C with 
microwave irradiation. After cooling, the appropriate imine (10 mmol) and ethyl 2-
bromoacetate (12 mmol) were added to the reaction vessel and the mixture was placed in 
the microwave reactor for 30 min at 100 °C. The reaction mixture was filtered through 
Celite to remove the zinc catalyst and then diluted with CH2Cl2 (50 mL). This solution 
was washed with saturated ammonium chloride solution (20 mL) and 25% ammonium 
hydroxide (20 mL), and then with dilute HCl (40 mL), followed by water (40 mL). The 
organic phase was dried over anhydrous Na2SO4 and the solvent was removed in vacuo. 
The crude product was isolated by flash column chromatography over silica gel (hexane: 
ethyl acetate gradient). 
 
General method IV: desilylation of TBDMS-protected β-lactams. To a solution of the 
appropriately protected phenol (10 mmol) in THF (50 mL) was added 1.5 equivalents of 
1M tetrabutylammonium fluoride. The solution was stirred in an ice-bath for 15 min and 
the reaction was monitored by TLC and IR. The reaction mixture was diluted with EtOAc 
(100 mL) and quenched with 10% HCl (100 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (2 x 50 mL). The organic layer was washed with 
water (100 mL) and brine (100 mL) and was dried with anhydrous Na2SO4. The crude 
product was isolated by flash column chromatography over silica gel (hexane: ethyl 
acetate gradient) and was used immediately in the following reaction without any further 
purification.  
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General method V: debenzylation of Bn-protected β-lactams. The benzyloxy 
protected -lactam (2 mmol) was dissolved in ethanol: ethyl acetate (50 mL; 1:1 mixture) 
and hydrogenated over 10%% Pd/C (1.2 g) at room temperature until complete, as 
indicated by TLC. The catalyst was filtered, the solvent was removed under vacuum and 
the product was isolated by flash column chromatography over silica gel (hexane: ethyl 
acetate gradient). 
 
General method VI. A solution of β-lactam (1 mmol) in anhydrous THF (25 mL) was 
stirred at -78 °C under an inert atmosphere. Lithium diisopropylamide (LDA) (2M, 5 
mmol) was added quickly and the solution was stirred at -78 °C for 5 min. A solution of 
4-hydroxybenzaldehyde (3 mmol) in anhydrous THF (12.5 mL) was added to the reaction 
mixture and it was stirred at -78 °C for 30 min and then poured slowly into a saturated 
sodium chloride solution (50 mL). Ethyl acetate (25 mL) was added, the organic layer 
was separated and dried with anhydrous Na2SO4. Evaporation of the solvent yielded a 
yellow solid residue which was purified by column chromatography (eluent: n-
hexane:ethyl acetate; 4:1). 
 
1,4-bis(4-Hydroxyphenyl)azetidin-2-one (15) was prepared from imine 10 and ethyl 2-
bromoacetate according to general method III. The crude product 4-(4-
(benzyloxy)phenyl)-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)azetidin-2-one (15a) was 
isolated by flash column chromatography over silica gel (hexane: ethyl acetate gradient) 
as a brown oil. This product was immediately desilylated according to general method IV 
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to form 4-(4-(benzyloxy)phenyl)-1-(4-hydroxyphenyl)azetidin-2-one (15b), which was 
debenzylated according to general method V to afford the product 15 as a white solid 
(0.9% overall yield), mp 180 ˚C. IR (KBr): ν̃ = 1715 (s; ν(C=O)), 3306 cm-1 (s; ν(O−H)). 
1H NMR (CD3OD) δ 2.80-2.84 (m, 1H, H3), 3.48 (dd, 1H, J = 5.0 Hz, 14.6 Hz, H3), 4.98-
4.99 (m, 1H, H4), 6.67-6.72 (m, 2H, ArH), 6.79-6.81 (m, 2H, ArH), 7.13 (d, 2H, J = 8.5 
Hz, ArH), 7.21 (d, 2H, J = 8.0 Hz, ArH). 13C NMR (CD3OD) δ 45.3 (C3), 53.4 (C4), 
114.3, 114.3, 114.6, 114.9, 117.9, 121.7, 126.7, 128.3, 128.5, 129.6, 153.3, 156.9 (ArC), 
164.8 (C=O). HRMS (ESI): m/z calcd for C15H13NO3 + H
+ (M + H)+: 256.0968; found: 
256.0967. 
 
1,4-bis(4-Benzyloxyphenyl)azetidin-2-one (17) was prepared from imine 13 and ethyl 
2-bromoacetate according to general method III. The product was obtained as a yellow 
powder (32% yield), mp 135-136 ˚C. IR (KBr): ν̃ = 1745 cm-1 (s; ν(C=O)). 1H NMR 
(CDCl3) δ 2.83-2.86 (m, 1H, H3), 3.52 (dd, 1H, J = 14.8 Hz, 5.3 Hz, H3), 5.02 (s, 2H, 
OCH2), 5.08 (s, 2H, OCH2), 5.10-5.11 (m, 1H, H4), 6.94 (d, J = 9.0 Hz, 2H, ArH), 7.02 
(d, J = 8.5 Hz, 2H, ArH), 7.15-7.39 (m, 14H, ArH). 13C NMR (CDCl3) δ 46.3 (C3), 52.6 
(C4), 69.2 (OCH2), 69.3 (OCH2), 115.1, 115.3, 117.8, 127.6, 127.7, 127.7, 127.8, 127.9, 
128.4, 128.4, 130.5, 131.2, 136.9, 136.9, 154.4, 158.3 (ArC), 163.9 (C=O). HRMS (ESI): 
m/z calcd for C29H25NO3 + H
+ (M + H)+: 436.1907; found: 436.1920. 
 
1,4-bis(4-Methoxyphenyl)azetidin-2-one (18) was prepared from imine 13 according to 
general method III. Evaporation of the solvent yielded a brown solid residue which was 
purified by column chromatography (eluent: CH2Cl2) to afford the β-lactam as brown 
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crystals (36% yield), mp 134 °C.54 IR (KBr): ν̃ = 1751 cm-1 (s; ν(C=O)). 1H NMR 
(CDCl3) δ 2.92 (dd, 1H, J = 12.6 Hz, J = 2.5 Hz, H3), 3.53 (dd, 1H, J = 9.5 Hz, J = 5.5 
Hz, H3), 3.75 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.94, (dd, 1H, J = 2.7 Hz, J = 5.5 Hz, 
H4), 6.80 (d, 2H, J = 9.0 Hz, ArH), 6.92 (d, 2H, J = 8.5 Hz, ArH), δ 7.24-7.30 (2xd, 
overlapping, 4H, J = 8.5 Hz, ArH). 13C NMR (CDCl3) δ 46.6 (C3, CH2), 53.3 (C4, CH), 
54.9 (OCH3), 55.3 (OCH3), 113.8, 115.9, 117.7, 126.8, 129.7, 131.0, 155.4, 159.2, 163.8 
(C=O). HRMS (ESI): m/z calcd for C17H17NO3 + Na
+ (M + Na)+: 306.1101; found: 
306.1115. 
 
1,4-bis(4-Hydroxyphenyl)-3-phenylazetidin-2-one (19). 4-(4-(Benzyloxy)phenyl)-1-(4-
((tert-butyldimethylsilyl)oxy)phenyl)-3-phenylazetidin-2-one (19a) was prepared from 
imine 10 and 2-phenylacetyl chloride according to general method II. This product was 
immediately desilylated according to general method IV to form 4-(4-
(benzyloxy)phenyl)-1-(4-hydroxyphenyl)-3-phenylazetidin-2-one (19b), which was 
debenzylated according to general method V to afford the product 19. It was obtained by 
column chromatography (hexane: ethyl acetate gradient) as a yellow gel (29% yield). IR 
(KBr): ν̃ = 1717 (s; ν(C=O)), 3327 cm-1 (s; ν(O−H)). 1H NMR (CD3OD) δ 4.24 (d, 1H, J 
= 2.5 Hz, H3), 4.96 (d, 1H, J = 2.0 Hz, H4), 6.72 (d, 2H, J = 9.0 Hz, ArH), 6.83 (d, 2H, J 
= 8.5 Hz, ArH), 7.21 -7.27 (m, 4H, ArH), 7.33-7.34 (m, 2H, ArH), 7.41-7.43 (m, 2H, 
ArH). 13C NMR (CD3OD) δ 65.7 (C3), 66.6 (C4), 117.1, 117.4, 120.8, 129.1, 129.2, 
129.4, 130.6 (ArC). HRMS (ESI): m/z calcd for C21H17NO3 + Na
+ (M + Na)+: 354.1101; 
found: 354.1102. 
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1,3,4-tris(4-Hydroxyphenyl)azetidin-2-one (20). 3,4-bis(4-(Benzyloxy)phenyl)-1-(4-
((tert-butyldimethylsilyl)oxy)phenyl)azetidin-2-one (20a) was prepared from imine 10 
and 4-benzyloxyphenylacetyl chloride according to general method II. This product was 
immediately desilylated according to general method IV to form 3,4-bis(4-
benzyloxy)phenyl)-1-(4-hydroxyphenyl)azetidin-2-one (20b), which was debenzylated 
according to general method V to afford the product 20 as an off-white powder (13% 
yield), mp 124 °C. IR (KBr): ν̃ = 1741 (s; ν(C=O)), 3427 cm-1 (s; ν(O−H)). 1H NMR 
(CDCl3) δ 4.14 (d, 1H, J = 2.5 Hz, H3), 4.95 (d, 1H, J = 2 Hz, H4), 6.67 (m, 1H, ArH), 
6.69 (m, 2H, ArH), 6.78 (m, 4H, ArH), 6.95 (s, 1H, ArH), 7.10 (m, 4H, ArH), 7.20 (m, 
1H, ArH), 9.35 (m, 3H, OH). 13C NMR (CDCl3) δ 62.5 (C3), 63.6 (C4), 114.9, 114.9, 
115.5, 115.6, 115.7, 118.6, 120.7, 125.4, 127.7, 127.8, 128.6, 129.3, 129.7, 130.1, 130.9, 
153.7, 155.4, 156.8, 157.5 (ArC), 165.3 (C=O). HRMS (ESI): m/z calcd for C21H17NO2 + 
H+ (M + H)+: 348.1230; found: 348.1233. 
 
1,4-bis(4-Hydroxyphenyl)-3-phenoxyazetidin-2-one (21). 4-(4-(Benzyloxy)phenyl)-1-
(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-phenoxyazetidin-2-one (21a) was obtained 
from imine 10 and 2-phenoxyacetyl chloride according to general method II. This 
product was immediately desilylated according to general method IV to form 4-(4-
(benzyloxy)phenyl)-1-(4-hydroxyphenyl)-3-phenoxyazetidin-2-one (21b), which was 
debenzylated according to general method V to afford the product 21 as a yellow powder 
(14% yield), mp 244 ˚C. IR (KBr): ν̃ = 1727 (s; ν(C=O)), 3349 cm-1 (s; ν(O−H)). 1H 
NMR (CD3OD) δ 5.48 (dd, 1H, J = 4.5 Hz, H4), 5.64 (d, 1H, J = 4.5 Hz, H3), 6.67-6.73 
(m, 4H, ArH), 6.80 (m, 2H, ArH), 6.88-6.91 (m, 1H, ArH), 7.15-7.24 (m, 6H, ArH). 13C 
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NMR (CD3OD) δ 61.4 (C4), 79.9 (C3), 108.6, 114.2, 114.5, 114.7, 117.4, 118.5, 121.0, 
122.9, 128.4, 128.9, 153.9, 156.5, 157.1 (ArC), 162.8 (C=O). HRMS (ESI): m/z calcd for 
C21H17NO4 + Na
+ (M + Na)+: 370.1050; found: 370.1062. 
 
1,4-bis(4-Hydroxyphenyl)-3-(naphthalen-2-yl)azetidin-2-one (22). 4-(4-
(Benzyloxy)phenyl)-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-(naphthalen-2-
yl)azetidin-2-one (22a) was obtained from imine 10 and 2-(naphthalen-2-yl)acetyl 
chloride according to general method II. This product was immediately desilylated 
according to general method IV to form 4-(4-(benzyloxy)phenyl)-1-(4-hydroxyphenyl)-3-
(naphthalen-2-yl)azetidin-2-one (22b), which was debenzylated according to general 
method V to afford the product 22 as a cream powder (83% yield), mp 229 ˚C. IR (KBr): 
ν̃ = 1707 (s; ν(C=O)), 3417 cm-1 (s; ν(O−H)). 1H NMR (DMSO-d6) δ 4.48 (s(br), 1H, H3), 
5.18 (s(br), 1H, H4), 6.72 (d, 2H, J = 8.5 Hz, ArH), 6.79 (d, 2H, J = 8.0 Hz, ArH), 7.17 
(d, 2H, J = 8.5 Hz, ArH), 7.30 (d, 2H, J = 8.0 Hz, ArH), 7.45 (d, 1H, J = 8.5 Hz), 7.52-
7.54 (m, 2H, ArH), 7.90-7.97 (m, 4H, ArH), 9.36 (s, 1H, OH), 9.59 (s, 1H, OH). 13C 
NMR (DMSO-d6) δ 61.9 (C3), 64.2 (C4), 115.5, 115.7, 118.7, 125.5, 126.1, 126.3, 126.5, 
127.6, 127.6, 127.7, 127.9, 128.5, 129.2, 132.3, 132.7, 133.0, 153.9, 157.6 (ArC), 164.7 
(C=O); HRMS (ESI): m/z calcd for C25H19NO3 + Na
+ (M + Na)+: 404.1257; found: 
404.1249. 
 
1,4-bis(4-Hydroxyphenyl)-3,3-diphenylazetidin-2-one (23). 4-(4-(Benzyloxy)phenyl)-
1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,3-diphenyl azetidin-2-one (23a) was 
obtained from imine 10 and 2,2-diphenylacetyl chloride according to general method II. 
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This product was immediately desilylated according to general method IV to form 4-(4-
(benzyloxy)phenyl)-1-(4-hydroxyphenyl)-3,3-diphenyl azetidin-2-one (23b), which was 
debenzylated according to general method V to afford the product 23 as a white powder 
(75% yield), mp 115˚C. IR (KBr): ν̃ = 1775 (s; ν(C=O)), 3359 cm-1 (s; ν(O−H)). 1H NMR 
(DMSO-d6) δ 5.95 (s, 1H, H4), 6.53 (d, 2H, J = 8.0 Hz, ArH), 6.72 (d, 2H, J = 9.0 Hz, 
ArH), 6.96-7.09 (m, 7H, ArH), 7.21 (d, 2H, J = 9.0 Hz, ArH), 7.28-7.32 (m, 1H, ArH), 
7.39-7.43 (m, 2H, ArH), 7.66 (d, 2H, J = 8.0 Hz, ArH), 9.37 (s, 1H, OH), 9.39 (s, 1H, 
OH). 13C NMR (DMSO-d6) δ 65.3 (C3), 71.1 (C4), 115.0, 115.5, 118.9, 124.9, 126.54, 
127.2, 127.9, 127.9, 128.7, 128.9, 128.9, 138.1, 141.1, 153.9, 156.9 (ArC), 165.7 (C=O). 
HRMS (ESI): m/z calcd for C27H21NO3 + H
+ (M + H)+: 408.1594; found: 408.1594. 
 
1,4-bis(4-Hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)azetidin-2-one (24). 4-(4-
(Benzyloxy)phenyl)-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3-(3,4,5-
trimethoxyphenyl)azetidin-2-one (24a) was obtained from imine 10 and 2-(3,4,5-
trimethoxyphenyl)acetyl chloride according to general method II. This product was 
immediately desilylated according to general method IV to form 4-(4-
(benzyloxy)phenyl)-1-(4-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(24b), which was debenzylated according to general method V to afford the product 24 as 
a white solid (46% yield), mp 122-124 ˚C. IR (KBr): ν̃ = 1615 (s; ν(C=O)), 3414 cm-1 (s; 
ν(O−H)). 1H NMR (CDCl3) δ 3.30 (s, 2H, OH), 3.66 (s, 3H, OCH3), 3.77 (s, 6H, 
2xOCH3), 4.23 (s, 1H, H3), 5.13 (s, 1H, H4), 6.63 (s, 2H, ArH), 6.69 (m, 2H, ArH), 6.78 
(m, 2H, ArH), 7.13 (m, 2H, ArH), 7.26 (m, 2H, ArH). 13C NMR (CDCl3) δ 56.4 (OCH3), 
60.5 (OCH3), 62.2 (C3), 64.8 (C4), 105.4, 115.9, 116.2, 119.2, 128.4, 128.3, 129.7, 131.1, 
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137.3, 153.6, 154.3, 158.1 (ArC), 165.1 (C=O). HRMS (ESI): m/z calcd for C24H23NO6 + 
Na+ (M + Na)+: 444.1418; found: 444.1440. 
 
1,3-bis(4-Hydroxyphenyl)-4-(3,4,5-trimethoxyphenyl)azetidin-2-one (25). 3-(4-
(Benzyloxy)phenyl)-4-(3,4,5-trimethoxyphenyl)-1-(4-
((trimethylsilyl)oxy)phenyl)azetidin-2-one (25a) was obtained from imine 11 and 4-
benzyoxyphenylacetyl chloride, according to general method II. This product was 
immediately desilylated according to general method IV to form 3-(4-
(benzyloxy)phenyl)-1-(4-hydroxyphenyl)-4-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(25b), which was debenzylated according to general method V to afford the product 25 as 
a brown powder (54% yield), mp 221 ˚C. IR (NaCl): ν̃ = 1727 (s; ν(C=O)), 3427 cm-1 (s; 
ν(O−H)). 1H NMR (CDCl3) δ 3.83 (s, 5H, OCH3), 3.87 (s, 3H, OCH3), 4.20 (d, 1H, J = 
2.5 Hz, H3), 4.78 (d, 1H, J = 2.5 Hz, H4), 6.56 (s, 2H, ArH), 6.77-6.83 (m, 4H, ArH), 
7.17 (d, J = 8.6 Hz, 2H, ArH), 7.26-7.28 (m, 2H, ArH). 13C NMR (DMSO-d6) δ 55.9 
(OCH3), 59.9 (OCH3), 62.7 (C3), 63.3 (C4), 103.7, 115.6, 115.6, 118.7, 125.2, 128.7, 
129.3, 133.5, 137.4, 153.3, 153.9, 156.9 (ArC), 165.4 (C=O). HRMS (ESI): m/z calcd for 
C24H23NO6
+ (M)+: 421.1525; found: 421.1531. 
 
3-[(Hydroxy-4-hydroxyphenyl)methyl]-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (26) was prepared from β-lactam 16 according to 
general method VI. The product 26 was obtained as orange crystals (31% yield), mp 130-
133 °C. IR (NaCl): ν̃ = 1749 (s; ν(C=O)), 3210 cm-1 (s; ν(O−H)). 1H NMR (CDCl3) δ 
3.43-3.44 (0.25H, m, H3), 3.46 (dd, 0.75H, J = 2.0 Hz, 6.3 Hz, H3), 4.78 (d, 0.75H, J = 
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2.0 Hz, H4), 5.08-5.11 (m, 1H, H5), 5.28-5-29 (m, 0.25H, H4), 6.97-7.42 (m, 14H, ArH). 
13C NMR (CDCl3) δ 55.3, 57.2 (CH, C4), 65.4, 66.2 (CH, C3) 70.2, 71.4 (CH, C5), 116.7, 
116.9, 123.7, 123.9, 125.3, 128.7, 132.9, 139.5 (ArC), 165.2, 165.8 (C2, C=O). HRMS 
(ESI): m/z calcd for C26H27NO7 + Na
+ (M + Na)+: 488.1680; found: 488.1661. 
 
3-[Hydroxy-(4-hydroxyphenyl)methyl]-1,4-bis(4-hydroxyphenyl)azetidin-2-one (28). 
1,4-bis(4-Benzyloxyphenyl)-3-[hydroxy-(4-hydroxyphenyl)]methylazetidin-2-one (27) 
was prepared from β-lactam 17 according to general method VI to afford 27 as an oil 
(12% yield). IR (NaCl): ν̃ = 1731 (s; ν(C=O)), 3429 cm-1 (s; ν(O−H)). 1H NMR (CDCl3) 
δ 3.41-3.42 (m, 1H, H3), 4.73 (d, J = 2.0 Hz, 1H, H4), 5.01 (s, 2H, OCH2), 5.03 (s, 2H, 
OCH2), 5.08 (d, J = 7.5 Hz, 1H, H5), 6.83-7.42 (m, 22H, ArH). HRMS (ESI): m/z calcd 
for C36H31NO5 – H+ (M – H)+: 556.2129; found: 556.2173. β-Lactam 28 was prepared 
from 27 according to general method V. The crude product was isolated by flash column 
chromatography over silica gel (hexane: ethyl acetate gradient) to afford the product 28 
as an amber oil (65% yield). IR: NaCl film υmax: 3325 (OH), 1721 (C=O) cm-1. 1H NMR 
(CDCl3) δ 3.32-3.40 (m, 1H, H3), 4.70-4.72 (m, 0.5H, H4), 5.00 (d, 0.5H, J = 6.5 Hz H5), 
5.13 (s, 0.5H, H4), 5.14 (d, J = 4.0 Hz, 0.5H, H5), 6.65-7.13 (m, 12H, ArH). 
13C NMR 
(CDCl3) δ 59.6 (C3), 60.4 (C4), 74.5 (C5), 114.2, 114.4, 114.5, 114.6, 114.8, 118.1, 126.6, 
126.6, 127.4, 129.2, 132.2, 132.6, 153.4, 155.3, 157.7 (ArC), 167.3 (C2). HRMS (ESI): 
m/z calcd for C22H19NO5 + Na
+ (M + Na)+: 400.1155; found: 400.1149. 
 
3-[Hydroxy-(4-hydroxyphenyl)-methyl]-1,4-bis-(4-methoxyphenyl)-azetidin-2-one 
(29) was prepared from β-lactam 18 according to general method VI. Evaporation of 
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solvent yielded a brown solid residue which was purified using column chromatography 
(DCM: EtOAc 4:1) to obtain the product 29 as an orange gel  (20% yield). IR (NaCl): ν̃ = 
1731 (s; ν(C=O)), 3384 cm-1 (s; ν(O−H)). 1H NMR (400 MHz, CDCl3) δ 3.34-3.36 (q, 
0.38H, J = 2.0 Hz, H3), 3.40-3.42 (q, 0.62H, J = 3.4 Hz, H3), 3.69 (s, 3H, OCH3), 3.72 (s, 
3H, OCH3), 4.72-4.73 (d, 0.6H, J = 2.0 Hz, H4), 4.97-4.99 (d, 0.6H, J = 6.2 Hz, H5 ), 
5.11 (s, 0.4H, H5), 5.16 (d, 0.4H, J = 4.1 Hz, H4), 6.72-6.79 (m, 6H, ArH), 6.96-7.00 (m, 
2H, ArH), 7.11-7.23 (m, 4H, ArH). 13C NMR (100 MHz, CDCl3): δ 53.0, 55.9, 57.2 (C4), 
65.4, 66.1 (C3),  69.5, 71.7 (C5), 113.9, 115.1, 115.2, 118.2, 118.3, 126.6, 126.8, 127.7, 
128.4, 128.9, 130.3, 130.4, 131.7, 132.4, 155.5, 155.9, 158.8, 159.1, 165.4 (C=O), 165.5 
(C=O). HRMS (ESI): m/z calcd for C24H23NO5 + Na
+ (M + Na)+: 428.1468; found: 
428.1494. 
 
3-(Hydroxy-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methyl-4-(4-methoxyphenyl)-1-
(3,4,5-trimethoxyphenyl)azetidin-2-one (30). β-Lactam 26 (10 mmol) was dissolved in 
anhydrous acetone (100 mL) and anhydrous potassium carbonate (160 mmol) was added. 
The mixture was stirred gently for 10 min under a nitrogen atmosphere and 1-(2-
chloroethyl)pyrrolidine hydrochloride (40 mmol) was added. The mixture was refluxed 
until the reaction was complete, as indicated by TLC. The solution was filtered, the 
solvent was removed under reduced pressure and the residue was purified by column 
chromatography (eluent: CH2Cl2). The product 30 was obtained as a yellow gel (30% 
yield). 1H NMR (CDCl3) δ 1.89 (s, 4H, C(CH2)2C), 2.81 (s, 4H, CH2NCH2), 3.04 (s, 2H, 
CH2N), 3.41-3.48 (m, 1H, H3), 3.71 (s, 6H, OCH3), 3.78 (s, 6H, OCH3), 4.21 (s, 2H, 
CH2-O), 4.83 (d, 0.5H, J = 2.0 Hz, H4), 5.08 (d, 0.5H, J = 5.5 Hz, H5), 5.16 (d, 0.5H, J = 
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2.5 Hz, H4), 5.34 (d, 0.5H, J = 4.0 Hz, H5), 6.97-7.42 (m, 14H, ArH). HRMS (ESI): m/z 
calcd for C32H38N2O7 + H
+ (M + H)+: 563.2752; found: 563.2769. 
 
Biochemical Evaluation. All biochemical assays were performed in triplicate on at least 
three independent occasions for the determination of mean values reported. 
 
ER Fluorescent Polarisation Assay. Competitive binding affinity experiments were 
carried out using purified baculovirus-expressed human ERα and ERβ and fluoromone, a 
fluorescein-labeled estrogen ligand. The ERα and ERβ fluorescence polarization based-
competitor assay kits were obtained from Invitrogen (P2698 [α] and P2700 [β]). The 
assay was performed using a protocol described by the manufacturer.37-38 The 
recombinant ER and the fluorescent estrogen ligand were removed from the -80 °C 
freezer and thawed on ice (4 °C) for one-hour prior to use. The fluorescent estrogen (2 
nM) was added to the ER (40 nM for ERα and 20 nM for ERβ) and screening buffer 
(provided; 100 nM potassium phosphate (pH 7.4), 100 μg/ml BGG, 0.02 M NaN3) was 
added to make up a final volume that was dependent on the number of tubes used. Test 
compound, 1 μL, in the desired range of concentrations, was added to the wells of a 96-
well black plate (Greiner, 6 mm diameter) to which 49 μL screening buffer was then 
added. 50 μL of the fluorescent estrogen/ER complex was added to make up a total 
volume of 100 μL. A vehicle control contained 1% ethanol (v/v). A negative control 
contained 50 μL of screening buffer and 50 μL of fluorescent estrogen/ER complex. This 
control was used to determine the polarization value when no competitor was present 
(theoretical maximum polarization). 1 μL of 1 mM β-estradiol (endogenous ligand) (final 
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concentration in well of 10 μM) was used as a positive control (minimum polarization 
value). The plates were incubated in the dark at room temperature for 2 hours and were 
mixed by shaking on a plate shaker. The fluorescence polarization values were read using 
485 nM excitation and 530 nM emission interference filters. IC50 values were calculated 
using GraphPad Prism software.55  
 
ER FRET Assay for Determination of Agonist or Antagonist Binding. The 
Lanthascreen® ER FRET assay (Invitrogen) was used to determine the binding mode of 
test compound 20 as described in the manufacturers protocol.56 Briefly, nuclear receptor 
buffer K was prepared by adding DTT to give a final concentration of 5 mM DTT. This 
buffer was used for all other dilutions. A ‘no ligand’ control of DMSO (2% v/v final 
concentration) was used to show minimum binding. β-Estradiol (2 µM final 
concentration) was used as a positive control. Compound serial dilutions in DMSO were 
prepared in a 96-well plate before transfer to a 384-well plate. 1 µL of a 10 mM solution 
of compound 20 in DMSO was added to 49 µL buffer. 10 µL of this dilution was added 
into each well. To make a 4X (12 nM) dilution of Fluoromone ES2 using a stock 
concentration of 1800 nM, 6.7 µL of fluoromone was added to 993 µL of buffer. 5 µL of 
this mixture was added to each well. ERα was thawed for one hour on ice prior to use and 
diluted with cold buffer. The TR-FRET buffer is prepared immediately prior to use. 
Receptor and fluorescein solution are added to the 384-well assay plate and the plate is 
read at wavelengths of 520nm and 495nm. IC50 values were calculated using GraphPad 
Prism Software.55  
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MTT Assay for Measurement of Antiproliferative Effects. The human breast tumour 
cell line MCF-7 was cultured in Eagles minimum essential medium in a 95%O2/5% CO2 
atmosphere at 37oC with 10% fetal bovine serum, 2 mM L-glutamine and 100 µg/mL 
penicillin/streptomycin. The medium was supplemented with 1% non-essential amino 
acids. Cells were trypsinised and seeded at a density of 5 x 103 cells/well in a 96-well 
plate and incubated at 37oC for 24 hr. After this time they were treated with 2 µL 
volumes of test compound in ethanol (nine final concentrations between 1 nM-100 µM) 
Control wells contained the equivalent volume of the vehicle ethanol (1% v/v). After 72 
hr, the culture medium was carefully removed, the cells were washed with 100 µL 
phosphate buffered saline (PBS) and 50 µL MTT (dissolved in PBS) was added, to give a 
final concentration of 1 mg/mL MTT. Cells were incubated for 3 hours in darkness at 
37oC. After this, 200 µL DMSO was added to each well, cells were kept in darkness for 
20 min at room temperature and the absorbance at 595 nm was read using a Dynatech 
MR5000 plate reader. The absorbance value of control cells (no compound added) was 
set as 100% cell viability and, from this, graphs of absorbance versus cell density per 
well were prepared to assess cell viability using GraphPad Prism software.55  
 
Lactate Dehydrogenase Assay for Measurement of Cytotoxicity. Cytotoxicity was 
determined using the CytoTox 96 non-radioactive cytotoxicity assay (Promega) 
following the manufacturer’s protocol.57 Briefly, MCF-7 cells were seeded in 96-well 
plates, incubated for 24 hr and then treated with test compounds 16, 26 and 30 as 
described in the MTT assay above. After 72 hr, 20 μL of ‘lysis solution (10X)’ was added 
to control wells and the plate was incubated for a further 1 hr to ensure 100% death. 50 
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μL of supernatant was carefully removed from each well and transferred to a new 96-well 
plate. 50 μL of reconstituted ‘substrate mix’ was added and the plate was placed in the 
dark at room temperature for 30 min. After this period, 50 μL of ‘stop solution’ was 
added to each well and the absorbance was read at a wavelength of 490 nm using a 
Dynatech MR5000 plate reader. The percentage cell death at 10 μM was calculated. 
 
Cell Cycle Analysis using Flow Cytometry. MCF-7 cells were seeded at a density of 18 
x 105 cells/mL in medium (5 mL)(900,000 cells per flask). After 24 hr the cells were 
treated with 50 μL of ethanol (1% v/v)(vehicle control) and range of concentrations of 
selected compounds 16, 26 or 30 (10 nM-10 μM 1% v/v). They were incubated for 24 hr, 
48 hr (compound 26, 10 μM) or 72 hr (compound 26, 10 μM). Following incubation, 
media was transferred to a vial and the cells were trypsinized. Cells were centrifuged for 
10 min at 600g. The supernatant was decanted, the pellet resuspended in ice-cold PBS 
(200 μL) and added to the vial containing the media. Subsequently ice-cold 70% 
ethanol/PBS (2 mL) was slowly added to the tube as it was gently vortexed. Samples 
were kept at -20 °C for a minimum of one hour. After the fixation FBS (5 μL) was added 
to the samples. Ethanol was removed by centrifugation and pellets were incubated in 
FACSflow sheath fluid (400 mL) supplemente)d with RNase A (10 mg/mL)(Sigma 
Aldrich, St Louis, MO, USA) and propidium iodide (100 mg/mL (Sigma Aldrich, St 
Louis, MO, USA). The samples were incubated in the dark for a minimum of 30 min at 
37 °C. The samples were read at 488 nM using FACSCalibur™ flow cytometer (Becton 
Dickinson). The FACS data for 10,000 cells was analysed using BD CellQuest™ and the 
data was stored as frequency histograms. 
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Western Blots 
Tubulin Polymerisation Assay. Tubulin depolymerization was quantified by using a 
modified version of a previously documented method.58 MCF-7 cells were treated with 
vehicle [0.1% ethanol (v/v)] or indicated concentrations of 26 (1 µM), paclitaxel (1 µM) 
or nocodazole (1 µM) for 4 hours. Cells were harvested into MT-preserving buffer (0.1 
M PIPES (pH 6.9), 2 M glycerol, 5 mM MgCl2, 2 mM EGTA, 0.5% Triton X-100, and 
protease inhibitors (Roche Diagnostics Ltd, UK) supplemented with 4 μM paclitaxel to 
maintain stability of assembled microtubules during isolation. The supernatant containing 
unpolymerized tubulin was clarified by centrifugation (16,000g for 45 min) using a 
Sorvell and separated from the pellet containing polymerized tubulin. The pellet was 
washed once in MT-preserving buffer before being denatured in PARP buffer (300 
μL)(62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue, 6M 
Urea and 5% β-mercaptoethanol). Samples were stored at -80 °C. Before use 1M DTT 
(20 µL) was added to both the supernatant and pellet samples. 2X Laemmli buffer (180 
µL)(62.5 mM Tris-Hcl, pH 6.8, 6 M urea, 2% SDS, 10% glycerol, and 0.00125% 
bromphenol blue) was added to the supernatants. All samples were boiled at 100 °C for 3 
minutes and loaded equally (30 µg protein). Proteins were separated on 10% SDS-PAGE 
gels and transferred onto nitrocellulose (Millipore). Membranes were blocked in 5% non-
dry fat milk/TBST for 1 hour, anti-α-tubulin primary antibody [1:1000] (Millipore) for 2 
hours and anti-mouse HRP-conjugated secondary antibody [1:1000] (Promega) for 1 hour 
at RT. All blots were probed with anti-GAPDH antibody [1:1000] (Millipore) to confirm 
equal loading. Proteins were detected using Immobilon™ western 
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electrochemiluminescence reagent (Milipore) on Kodak X-Omat LS film and developed 
using a Fuji X-rayprocessor. 
 
Evaluation of expression levels of anti-apoptotic proteins Bcl-2 and Mcl-1 
MCF-7 cells were seeded at a density of 500,000 cells/flask in T25 flasks. After 48 or 72 
hr, whole cell lysates were prepared from untreated cells or cells treated with vehicle 
control (EtOH, 0.1% v/v) or compound 26 (10 μM). Cells were harvested in RIPA buffer 
supplemented with protease inhibitors (Roche Diagnostics), phosphatase inhibitor 
cocktail 2 (Sigma-Aldrich) and phosphatase inhibitor cocktail 3 (Sigma-Aldrich). Equal 
quantities of protein (as determined by a BCA assay) were resolved by SDS-PAGE 
(12%) followed by transfer to PVDF membranes. Membranes were blocked in 5% non-
dry fat milk/TBST for 1 hr. Membranes were incubated in the relevant primary antibodies 
at 4 ºC overnight, washed and incubated in horseradish peroxidase conjugated secondary 
antibody for 1 hr at rt and washed again. Enhanced chemiluminescence was used for 
detection of protein expression. Western blot analysis was performed using antibodies 
directed against Mcl-1 [1:1000] (Millipore) and Bcl-2 [1:500] (Millipore) followed by 
incubation with a horseradish peroxidase-conjugated anti-mouse antibody [1:1000] 
(Promega, Madison, WI, USA). All blots were probed with anti-GAPDH antibody 
[1:1000] (Millipore) to confirm equal loading. Proteins were detected using 
chemiluminescent western blot detection (Clarity Western ECL substrate) (Bio Rad) on 
the ChemiDoc MP System (Bio Rad). 
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Computational Procedures. Compound 26 was drawn in Accelrys Draw v4.1 with 
alternate isomers represented and converted to a 3D structure using CORINA v3.4.59 
Subsequent enumeration of correct protonation states and conformers were carried out 
using pkatyper (QUACPAC v1.6.3.160-61) and OMEGA v 2.5.1.4 respectively.62-63 
Compound 26  was docked using the ligand guided docking tool HYBRID (OEDocking 
v3.0.164) into the binding site of ERα (PDB ID: 2OUZ65) and the colchicine site of 
tubulin (PDB ID: 4O2B66). All hybrid dockings were refined by energy minimisation 
under the Pfrosst force field in MOE v2011.10.39 
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Non-Standard Abbreviations 
ER  Estrogen receptor 
FRET  Fluorescence resonance energy transfer 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
TBDMS Tert-butyldimethylsilane 
TMCS  Trimethylchlorosilane 
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Table 1. ERα and ERβ binding affinity values and antiproliferative activity in MCF-
7 cells for β-lactam compounds 
Compound 
 
IC50 
MCF-
7 
(μM)a 
IC50 
ERα 
(μM)b 
IC50 
ERβ 
(μM)b 
 R1 R2 R3 R4 R5 R6    
15 OH OH H H H H >50 13 56 
16 OCH3 OCH3 OCH3 H H H 0.04
25 Inactive Inactive 
19 OH OH H C6H5 H H >50 0.23 0.98 
20 OH OH H p-C6H4OH H H >50 1.1 4.8 
21 OH OH H OC6H5 H H >50 0.14 1.2 
22 OH OH H 2-naphthyl H H >50 0.15 1.1 
23 OH OH H C6H5 C6H5 H 45 0.04 0.019 
24 OH OH H 3,4,5-OCH3C2H6 H H >50 1.47 23 
25 OCH3 OH H p-C6H4OH H OCH3 >50 18 144 
26 OCH3 OCH3 OCH3 
 
H H 0.21 0.008 0.015 
28 OH OH H 
 
H H 49 Ndc Ndc 
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29 OCH3 OCH3 H 
 
H H 32 Ndc Ndc 
30 OCH3 OCH3 OCH3 
 
H H 3.8 Inactive Inactive 
1 β-Estradiol - 0.0057 0.0056 
2 Tamoxifen 4.1 0.061 0.19 
 
aIn vitro cytotoxicity data for compounds 15, 16, 19-26 and 28-30. IC50 values are half 
maximal inhibitory concentrations required to block the growth stimulation of MCF-7 
cells. Values represent the mean for three independent experiments performed in 
triplicate. The IC50 value obtained for 2 is in good agreement with the reported IC50 value 
for tamoxifen in human MCF-7 cells.67-68  
 
bCompetition assay for ERα and ERβ for compounds 15, 16, 19-26 and 28-30 using a 
human recombinant ERα and ERβ proteins and a fluorescent estrogen. IC50 values: the 
concentration of competitor that results in a half maximum shift in polarisation is 
calculated as the IC50 of the competitor. The ER binding values obtained are in agreement 
with the reported IC50 binding data for 2 (ER60.9 nM; ER188 nM) (Invitrogen). 
Values represent the mean for three independent experiments performed in duplicate.
 
cIC50 values for compounds 28 and 29 were not determined (nd). The % inhibition of 
ERα for these compounds at a concentration of 1 µM was 40% and 37% respectively. 
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The % inhibition of ERβ for these compounds at a concentration of 1 µM was 43% and 
75% respectively. For comparative purposes, compound 26 (1 µM) caused 93% 
inhibition of ERα and 94% inhibition of ERβ. 
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Figure Legends 
 
Figure 1. Estrogen Receptor Ligands 
 
Figure 2A. Evaluation of G2M arrest in MCF-7 cells exposed to compounds 16, 26, 
and 30. Cell cycle analysis of MCF-7 cells treated with vehicle control [1% (v/v) 
ethanol], or 10 nM, 100 nM, 1 μM and 10 μM (final concentrations) of compounds 16, 26 
and 30 at 24 hours. Cells were analysed by FACScan flow cytometry. Percentages of 
cells in different phases of the cell cycle are indicated. Values represent the mean ± 
S.E.M deviation for three separate experiments. 
 
Figure 2B. Differential effects of compound 26 on the cell cycle and apoptosis in 
MCF-7 cells.  Cells were treated with either vehicle [0.1% ethanol (v/v)] or 10 µM 
compound 26 for 24, 48 and 72 hours. Cells were then fixed, stained with PI, and 
analyzed by flow cytometry. Cell cycle analysis was performed on histograms of gated 
counts per DNA area (FL2-A). The number of cells with <2N (pre-G1), 2N (G0G1), and 
4N (G2M) DNA content was determined with CellQuest software. The sub-G1 peak is 
indicative of apoptosis. Statistical analysis was performed using GraphPad Prism 
software.55 A two-way ANOVA was employed to determine significant differences 
between vehicle controls and treated samples. Values represent the mean ± S.E.M. for 
two separate experiments.  
 
 53 
 
Figure 3. β-Lactam 26 induces depolymerization of tubulin in MCF-7 cells. The 
effect of β-lactam 26 on the microtubule network of MCF-7 breast cancer cells was 
examined by a sedimentation assay and western blotting. Cells were treated with vehicle 
[0.1% ethanol (v/v)], β-lactam 26, paclitaxel or nocodazole (1μM) for 4 hr before being 
lysed in MT preserving buffer. Unpolymerized and polymerized fractions were separated 
by centrifugation and collected as supernatant (S) and pellet (P) fractions respectively. 
Samples were separated by western blotting and probed with anti-α-tubulin antibody 
[1:1000] and anti-mouse secondary antibody [1:1000]. The soluble supernatant faction 
(S) contains unpolymerised tubulin and the insoluble pellet fraction (P) contains 
polymerized tubulin. GAPDH was used as a loading control [1:1000]. Results are 
representative of three separate experiments. 
 
Figure 4. β-Lactam 26 downregulates expression of the anti-apoptotic proteins Bcl-2 
and Mcl-1. MCF-7 cells were untreated (UT), treated with ethanol (0.1% v/v) (EtOH) or 
treated with compound 26 (10 μM). After 72 hr, cells were harvested and separated by 
SDS PAGE. The membrane was probed with anti-Bcl-2 [1:500] or anti-Mcl-1 [1:1000] 
antibodies. GAPDH was used as a loading control [1:1000]. Results are representative of 
three separate experiments. 
 
Figure 5. Predicted binding mode of β-lactam 26 in the ligand binding domain of 
ERα. Atoms are coloured as follows: carbon – grey; nitrogen – blue; oxygen – red. 
Dashed lines represent the non-covalent interaction between the ligand and receptor.  
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Figure 6. Predicted binding mode of β-lactam 26 in the tubulin-colchicine binding 
site. Colchicine is shown with a green scaffold and β-lactam 26 is shown with a grey 
scaffold. Atoms are coloured in both molecules as follows: nitrogen – blue; oxygen – red. 
Dashed lines represent the non-covalent interaction between the ligand and receptor.  
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Figure 6.  
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Scheme Legends 
 
Scheme 1. Synthesis of compound 9 and imines 10-14 a  
aReagents and conditions: (a) t-BuMe2SiCl, DBU, CH2Cl2, rt, until complete as indicated 
by TLC, 73%; (b) EtOH, reflux, 3 h, 74−100%. 
 
Scheme 2. Synthesis of β-lactams 15-25a 
a(a) Zn dust, (CH3)3SiCl, 40 °C, 15 min then 100°C, 2 min, microwave; BrCH2CO2Et, 
C6H6, 100 °C, 30 min, microwave, 32−43%; (b) TBAF, THF, 0 ˚C, 15 min; (c) H2, Pd/C, 
EtOH:EtOAc (1:1), rt, until complete as indicated by TLC; (d) R1R2CHCOCl, Et3N, 
CH2Cl2, reflux, 3 h. 
 
Scheme 3. Synthesis of β-lactams 26-30 a 
a(a) HOC6H4CHO, LDA, THF, -78 
oC, 30 min, 12−31%; (b) H2, Pd/C, EtOH:EtOAc 
(1:1), rt, until complete as indicated by TLC, 65%; (c) 1-(2-Chloroethyl)pyrrolidine 
hydrochloride, CH3COCH3, reflux, 2 h, 30%. 
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